Aurinia Pharmaceuticals Inc. (AUPH)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-03-23

Key Insights

Aurinia has appointed a new CEO, Kevin Tang, who is the Chair of the Board and has extensive experience in the life sciences industry.
The company has also appointed a new COO, Ryan Cole, and a new CFO, Michael Hearne, who both have relevant experience in their roles.
The previous CEO, President, COO, CMO, and CFO have all departed the company, which suggests a significant leadership change.

Insider Trading Filed: 2026-03-10

Key Insights

The reporting person, Greg Keenan, SVP and Chief Medical Officer of Aurinia Pharmaceuticals, disposed of 8,069 shares of common stock to satisfy tax withholding obligations upon the vesting of restricted stock units.
The transaction took place on March 6, 2026, and Keenan continues to beneficially own 154,449 shares of Aurinia's common stock.
The transaction appears to be a routine stock sale for tax purposes and does not suggest any significant changes in Keenan's position or outlook on the company.

Current Report Filed: 2026-02-26

Key Insights

Aurinia Pharmaceuticals reported its financial results for the three and twelve months ended December 31, 2025, providing an update on its recent business progress.
The company's financial performance and key operational updates are disclosed in the press release, which is attached as an exhibit to the 8-K filing.
Investors should review the financial results and progress updates to assess the company's performance and future prospects.

Annual Report Filed: 2026-02-26

Key Insights

Aurinia Pharmaceuticals reported steady revenue growth across their product lines, indicating strong commercial execution.
The company's cash and short-term investments position remains strong, providing ample liquidity to fund ongoing operations and future growth initiatives.
Aurinia is continuing to invest in R&D, with a focus on expanding their intellectual property portfolio and advancing their pipeline of new drug candidates.

Insider Trading Filed: 2026-02-23

Key Insights

Insider Stephen P. Robertson, EVP and General Counsel, sold 34,638 shares of Aurinia Pharmaceuticals Inc. (AUPH) on February 20, 2026, to cover tax withholding obligations on the vesting of restricted stock units.
After the transaction, Robertson still holds 483,296 shares directly, indicating he maintains a significant equity stake in the company.
The sale appears to be a routine transaction to cover tax liabilities rather than a strategic sale, suggesting no major concerns from this insider.

Insider Trading Filed: 2026-02-23

Key Insights

Joseph M. Miller, the Chief Financial Officer of Aurinia Pharmaceuticals Inc., disposed of 32,424 common shares to satisfy tax withholding obligations on vested restricted stock units.
This transaction represents a relatively small portion (5.5%) of Miller's total beneficial ownership of 556,703 common shares in the company.
Insider transactions, such as this, can provide insights into management's views on the company's prospects, although a single transaction should be interpreted cautiously.

Insider Trading Filed: 2026-02-23

Key Insights

Insider Peter Greenleaf, the Chief Executive Officer, has sold 100,171 shares of Aurinia Pharmaceuticals Inc. (AUPH) on February 20, 2026, likely to cover tax obligations on vested restricted stock units.
Greenleaf still holds a substantial 1,744,866 shares, indicating continued confidence in the company's long-term prospects.
This transaction represents a small portion (around 5%) of Greenleaf's total holdings, suggesting no major shift in his investment position.

Insider Trading Filed: 2026-02-23

Key Insights

The Chief Operating Officer, Matthew Maxwell Donley, disposed of 32,901 shares of Aurinia Pharmaceuticals Inc. (AUPH) on February 20, 2026, likely to satisfy tax withholding obligations upon the vesting of restricted stock units.
Donley's beneficial ownership in AUPH decreased from 695,801 shares to 662,900 shares following this transaction, representing a 4.7% reduction in his stake in the company.
Insider selling transactions, such as this one, can be a signal of management's confidence in the company's near-term outlook and may impact investor sentiment.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.